Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug

British Journal of Clinical Pharmacology
K BalnaveR G Shanks

Abstract

1 Observations were made in five subjects who exercised before and at 2, 3, 6, 8, 24, 33 and 48 h after the oral administration of placebo and 5, 10, 20 and 40 mg betaxolol. 2 The exercise heart rate remained constant at all times after the placebo. All doses of betaxolol significantly reduced the exercise tachycardia at all times. The maximum effect (34.4 +/- 2.2%) occurred after 40 mg. 3 There was a small decline in effect from the peak to 24 h when 40 mg produced a 23.3 +/- 2.7% reduction and a further decline to 48 h when there was a 14.6 +/- 1.8% reduction. 4 Plasma levels of betaxolol were measured in these studies. The peak plasma concentration occurred between 3 and 8 h with different doses. The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h. 5 The effects of 40 mg betaxolol, 200 mg atenolol, 160 mg propranolol, 160 mg oxprenolol, 400 mg sotalol and placebo on an exercise tachycardia were compared in five subjects who received all treatments in random order. 6 There was no significant difference in the maximum reduction produced in an exercise tachycardia by the different drugs. 7 The effect of all drugs decreased with time. The effect of oxprenolol had worn off a...Continue Reading

References

Nov 1, 1976·Clinical Pharmacology and Therapeutics·H C BrownR G Shanks
Aug 1, 1977·British Journal of Clinical Pharmacology·D G McDevitt
May 27, 1978·British Medical Journal·T ReybrouckE Meulepas
Nov 27, 1978·European Journal of Clinical Pharmacology·A P Douglas-JonesA Lee
Aug 1, 1978·British Journal of Clinical Pharmacology·J McAinshJ Young
Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Jan 1, 1970·Clinical Pharmacology and Therapeutics·D G ShandJ A Oates
Dec 1, 1976·British Journal of Clinical Pharmacology·S G CarruthersD G McDevitt

❮ Previous
Next ❯

Citations

Aug 1, 1990·Journal of Clinical Pharmacology·W H FrishmanD Behrman
Apr 1, 1992·Journal of Clinical Pharmacology·R L WilliamsL B Hogan
Jan 1, 1983·European Journal of Clinical Pharmacology·R Palminteri, G Kaik
Jan 1, 1990·Pharmacology & Therapeutics·T H Pringle, J G Riddell
Jul 5, 2001·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·E Vainio-JylhäR Huupponen
Jul 1, 1990·British Journal of Clinical Pharmacology·N A IrvineD G McDevitt
Feb 1, 1991·British Journal of Clinical Pharmacology·B J LipworthD G McDevitt
Mar 18, 1999·Australian and New Zealand Journal of Ophthalmology·J L Rait
Dec 1, 1987·Journal of Clinical Pharmacy and Therapeutics·J V Okopski
Sep 29, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·S M Al-SaidanR S Karthikeyan
Aug 1, 1987·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J H BauerA Lau
Jan 1, 1982·European Journal of Clinical Pharmacology·J T Salonen, R Palminteri
Jul 5, 2012·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Joanna LazniewskaTeresa Gabryelak
Apr 1, 1985·British Journal of Clinical Pharmacology·J G RiddellR G Shanks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.